在心力衰竭患者运动期间过度脏血管收缩
H R Middlekauff1, E U Nitzsche, C K Hoh
1Division of Cardiology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Circulation
|February 23, 2000
概括
心力衰竭患者在运动期间表现出过度的血管收缩,持续时间比健康人群更长. 肌肉代谢受体对这种反应的贡献在心力衰竭中减少.
科学领域:
- 心血管生理学心血管生理学
- 脏生理学 脏生理学
- 运动生理学 运动生理学
背景情况:
- 健康的人在静态运动期间表现出反射性脏皮质血管收缩.
- 肌肉代谢受体对这种运动诱导的血管收缩有显著的贡献.
- 在心力衰竭患者中,血管度对运动的反应尚不清楚.
研究的目的:
- 在心力衰竭患者的运动期间调查反射脏血管收缩.
- 为了在运动期间比较心力衰竭患者和健康对照人群之间的血管反应.
- 阐明肌肉代谢受体在心力衰竭中的血管收缩中的作用.
主要方法:
- 39名心力衰竭患者 (NYHA III-IV类) 和38名对照组接受了动态正子发射断层扫描以测量脏血液流量.
- 渐进的握手运动和握手后缺血性停滞被用来评估反射机制.
- 在持续握手和在循环停止期间量化脏血管收缩,以隔离肌肉代谢受体的影响.
主要成果:
- 与对照组相比,心力衰竭患者在持续握手期间表现出明显更大的脏血管收缩峰值 (70+/-13 vs 42+/-1 U,P=0.02).
- 与对照组相比,心力衰竭患者的血管收缩持续时间较长 (在2-5分钟内增加) (恢复到基线).
- 在手握后的循环停止期间,心力衰竭患者的血管收缩减弱 (20+/-5 vs 30+/-2 U,P=0.05),表明肌肉代谢受体贡献减少.
结论:
- 在心力衰竭患者的持续运动期间,反射性血管收缩的程度和持续时间被夸大了.
- 与健康个体相比,肌肉代谢受体在心力衰竭患者的反射血管收缩中扮演着的角色.
相关概念视频
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:22Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
01:20Exercise and Cardiovascular Response
6.7K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.7K
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632